Table 3.
Differences between the two groups regarding the necessity of invasive mechanical ventilation, admission to the ICU, improvement in the chest CT scan, the rate of mortality, and stay length in ICU and hospital.
| Adalimumab Group (n = 34) | Control Group (n = 34) | P-value (95% CI) | |
|---|---|---|---|
| Mechanical ventilation requirement | 4 (11.7%) | 3 (8.8%) | 1 |
| The need for non-invasive ventilation | 4 (11.7%) | 2 (5.8%) | 0.67 |
| Nasal or face mask or nasal oxygen therapy | 28 (82.3%) | 31 (91.1%) | 0.42 |
| The need for admission to the ICU | 5 (14.7%) | 5 (14.7%) | 1 |
| More than 50% improvement in chest CT scan | 8 (23.5%) | 5 (14.7%) | 0.74 |
| Length of hospital stay (day) | 12.18 ± 4.64 | 10.85 ± 5.29 | 0.27 (-1.08–3.73) |
| Length of ICU stay | 13 (8–18.5) | 9 (6.5–19.5) | 0.53 (-10.47–12.47) |
| Mortality (expired) | 4 (11.7%) | 4 (11.7%) | 1 |
Data are presented in numbers for qualitative data and median plus 25%-75% percentile for quantitative data. ICU: Intensive Care Unit; CT: Computed Tomography